Antibiotic therapy in patients with septic shock

European Journal of Anaesthesiology

Volumn 28, Issue 5, 2011, Pages 318-324

  Textoris, Julien ^a   Wiramus, Sandrine ^a   Martin, Claude ^a   Leone, Marc ^a  

^a HÔPITAL NORD   (France)

Author keywords

Antibiotic; De escalation; Empirical; Sepsis

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; DORIPENEM; ERTAPENEM; FLUCONAZOLE; GLYCOPEPTIDE; IMIPENEM; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; PROCALCITONIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACUTE PYELONEPHRITIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTIFICIAL VENTILATION; BACTERIAL PERITONITIS; BACTERICIDAL ACTIVITY; BACTEROIDES; BLOOD CULTURE; CANDIDIASIS; CAPILLARY PERMEABILITY; CATHETER INFECTION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; GLOMERULUS FILTRATION RATE; HAEMOPHILUS INFLUENZAE; HEMODYNAMICS; HOSPITAL INFECTION; HOST; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE; KIDNEY CLEARANCE; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; LENGTH OF STAY; LUNG INFECTION; MENINGOCOCCOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIAL GROWTH; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; MYCOPLASMA PNEUMONIAE; NEISSERIA MENINGITIDIS; NONHUMAN; PERITONITIS; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PSEUDOMONAS INFECTION; PULMONARY ASPIRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION; SURVIVAL; TREATMENT DURATION; URINARY TRACT INFECTION; YEAST;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC;

EID: 79959825740     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e328346c0de     Document Type: Review

References (57)

1. Wick JY. Enigmatic, but understandable: empiric therapy. Consult Pharm 2007; 22:691-694. (Pubitemid 47282434)
2. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 2007; 35:379-385. (Pubitemid 46148525)
3. Leone M, Bourgoin A, Cambon S, et al. Empirical antimicrobial therapy of septic shock patients: adequacy and impact on the outcome. Crit Care Med 2003; 31:462-467. (Pubitemid 36232941)
4. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-268. (Pubitemid 34754172)
5. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-685. (Pubitemid 27132946)
6. Lodise TP, Patel N, Kwa A, et al. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51:3510-3515. (Pubitemid 47519337)
7. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilatorassociated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
8. Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillintazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 2008; 46:862-867. (Pubitemid 351417187)
9. Garcin F, Leone M, Antonini F, et al. Nonadherence to guidelines: an avoidable cause of failure of empirical antimicrobial therapy in the presence of difficult-to-treat bacteria. Intensive Care Med 2010; 36:75-82.
10. Nachtigall I, Tamarkin A, Tafelski S, et al. Impact of adherence to standard operating procedures for pneumonia on outcome of intensive care unit patients. Crit Care Med 2009; 37:159-166.
11. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282:1458-1465. (Pubitemid 29493800)
12. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132:621-630. (Pubitemid 30217554)
13. Osih RB, McGregor JC, Rich SE, et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007; 51:839-844. (Pubitemid 46355264)
14. Thom KA, Schweizer ML, Osih RB, et al. Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study. BMC Infect Dis 2008; 8:116.
15. Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008; 32 (Suppl 2):S87-S91.
16. Schelenz S. Management of candidiasis in the intensive care unit. J Antimicrob Chemother 2008; 61 (Suppl 1):i31-34.
17. Textoris J, Wiramus S, Martin C, Leone M. Overview of antimicrobial therapy in intensive care units. Expert Rev Anti Infect Ther 2011; 9:97-109.
18. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327.
19. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36:222-231.
20. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goaldirected therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045-1053.
21. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009; 180:861-866.
22. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a five fold reduction of survival in human septic shock. Chest 2009; 136:1237-1248.
23. Vincent J, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329.
24. Ca? runtu FA, Benea L. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointestin Liver Dis 2006; 15:51-56. (Pubitemid 43845269)
25. van de Beek D, de Gans J. Dexamethasone in adults with communityacquired bacterial meningitis. Drugs 2006; 66:415-427.
26. Arabi Y,Memish ZA, Balkhy HH, et al. Ventriculostomy-associated infections: incidence and risk factors. Am J Infect Control 2005; 33:137-143. (Pubitemid 40417928)
27. Bouza E, Pérez A, Muñoz P, et al. Ventilator-associated pneumonia after heart surgery: a prospective analysis and the value of surveillance. Crit Care Med 2003; 31:1964-1970. (Pubitemid 36900751)
28. Hayon J, Figliolini C, Combes A, et al. Role of serial routine microbiologic culture results in the initial management of ventilatorassociated pneumonia. Am J Respir Crit Care Med 2002; 165:41-46. (Pubitemid 34053355)
29. Michel F, Franceschini B, Berger P, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. Chest 2005; 127:589-597. (Pubitemid 40229322)
30. Blot S, Depuydt P, Vogelaers D, et al. Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. Infect Control Hosp Epidemiol 2005; 26:575-579. (Pubitemid 40896148)
31. Depuydt PO, Blot SI, Benoit DD, et al. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. Crit Care Med 2006; 34:653-659.
32. Beardsley JR, Williamson JC, Johnson JW, et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospitalacquired pneumonia. Chest 2006; 130:787-793. (Pubitemid 44423610)
33. Pea F, Viale P. Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock -does the dose matter? Crit Care 2009; 13:214.
34. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once-versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28:753-764.
35. Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009; 37:2071-2078.
36. Albanèse J, Léone M, Bruguerolle B, et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000; 44:1356-1358. (Pubitemid 30228320)
37. Georges B, Conil J, Seguin T, et al. Population pharmacokinetics of ceftazidime in intensive care unit patients: influence of glomerular filtration rate, mechanical ventilation, and reason for admission. Antimicrob Agents Chemother 2009; 53:4483-4489.
38. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45:755-773.
39. Gilbert D. Aminoglycosides. Principles of antiinfective therapy. Mandell, Douglas and Bennet's Principles and Practice of Infectious Diseases. Vol. 1. In: Moellering R, Mandel G, Bennet J, Dolin R, editors. Churchill Livingstone 2000. pp. 279-306.
40. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared to monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010; 38:1773-1785.
41. Micek ST, Welch EC, Khan J, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010; 54:1742-1748.
42. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/ meta-regression study. Crit Care Med 2010; 38:1651-1664.
43. Laupland KB, Gregson DB, Zygun DA, et al. Severe bloodstream infections: a population-based assessment. Crit Care Med 2004; 32:992-997. (Pubitemid 38471521)
44. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 2004; 32 (Suppl):S513-S526. (Pubitemid 39489024)
45. Depuydt P, Blot S. Antibiotic therapy for ventilator-associated pneumonia: de-escalation in the real world. Crit Care Med 2007; 35:632-633. (Pubitemid 46148562)
46. Soo Hoo GW, Wen YE, Nguyen TV, Goetz MB. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 2005; 128:2778-2787. (Pubitemid 41507640)
47. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilatorassociated pneumonia. Crit Care Med 2004; 32:2183-2190.
48. Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator- associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic 'blind' bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143:1121-1129.
49. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505-511.
50. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005; 128:2706-2713. (Pubitemid 41507631)
51. Chastre J, Wolff M, Fagon J, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588-2598. (Pubitemid 37443289)
52. Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology 1991; 100:1737-1742.
53. Hedrick TL, Evans HL, Smith RL, et al. Can we define the ideal duration of antibiotic therapy? Surg Infect (Larchmt) 2006; 7:419-432. (Pubitemid 44857095)
54. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitoninguided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-607. (Pubitemid 38264177)
55. Ibrahim EH, Ward S, Sherman G, et al. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-1115. (Pubitemid 32554320)
56. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27:355-362. (Pubitemid 32249978)
57. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilatorassociated pneumonia. Chest 2004; 125:1791-1799. (Pubitemid 38648413)